News
-
-
-
COMMUNIQUÉ DE PRESSE
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer reports solid financial results in 2024 with revenue up 2.9% and adjusted EBITDA up 4.1%. Strategies for growth include expansions and focus on biologics solutions. Bormioli Pharma integration to boost revenues from 2025 -
-
-
-
-
-
-